U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07433621) titled 'Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency' on Feb. 20.
Brief Summary: The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
XIAP Deficiency
Intervention:
DRUG: Quercetin
Quercetin will be administered orally at a weight adjusted dose for a maximum total daily dose of 4000mg/day, divided twice a day....